Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 7 Clinical trials evaluating adoptive cell therapy in patients with TNBC

From: Recent advances in therapeutic strategies for triple-negative breast cancer

Intervention

Register ID

Study population

Phase

Status

EGFR/ CD276

NCT05341492

EGFR/B7H3-positive advanced TNBC

I

Recruiting

ROR1-targeted CAR T cell (LYL797)

NCT05274451

ROR1 + relapsed or refractory TNBC

I

Recruiting

NKG2DL-targeting CAR-grafted gamma delta (γδ) T Cells

NCT04107142

Relapsed or refractory solid tumor

I

Unknown

c-Met RNA CAR T cells

NCT01837602

Metastatic breast cancer

0

Completed[170]

CART-TnMUC1 cells

NCT04025216

Advanced TnMUC1+ TNBC

I

Recruiting

Anti-meso-CAR vector transduced T cells

NCT02580747

Relapsed or chemotherapy refractory advanced TNBC

I

Recruiting

Mesothelin-specific chimeric antigen receptor-positive T Cells

NCT02792114

Metastatic HER2− breast cancer

I

Active, not recruiting

PD-1+ TILS

NCT05451784

Advanced or metastatic TNBC

I/II

Not yet recruiting

TC-510

NCT05451849

Advanced mesothelin-expressing Cancer

I/II

Recruiting

  1. CAR: chimeric antigen receptors; EGFR: epidermal growth factor receptor; HER: human epidermal growth factor receptor; ROR: receptor tyrosine kinase-like orphan receptor; TIL: tumor-infiltrating lymphocytes; and TNBC: triple-negative breast cancer
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us